Outlook Therapeutics Files 8-K with Corporate Updates
Ticker: OTLK · Form: 8-K · Filed: Mar 7, 2024 · CIK: 1649989
| Field | Detail |
|---|---|
| Company | Outlook Therapeutics, Inc. (OTLK) |
| Form Type | 8-K |
| Filed Date | Mar 7, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing, financials
Related Tickers: OTLK
TL;DR
OTLK filed an 8-K detailing corporate changes and financial filings.
AI Summary
Outlook Therapeutics, Inc. filed an 8-K on March 7, 2024, reporting on several key items. These include amendments to its articles of incorporation or bylaws, the submission of matters to a vote of security holders, and the filing of financial statements and exhibits. The company, formerly known as Oncobiologics, Inc., is incorporated in Delaware and is in the biological products sector.
Why It Matters
This filing provides crucial updates on the company's governance and financial reporting, which are important for investors to understand the current operational and legal status of Outlook Therapeutics.
Risk Assessment
Risk Level: medium — 8-K filings can indicate significant corporate events, but the specific details within this filing require further analysis to determine the precise risk level.
Key Players & Entities
- Outlook Therapeutics, Inc. (company) — Registrant
- Oncobiologics, Inc. (company) — Former company name
- March 7, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 001-37759 (identifier) — Commission File Number
- 38-3982704 (identifier) — IRS Employer Identification No.
FAQ
What specific amendments were made to Outlook Therapeutics' articles of incorporation or bylaws?
The filing indicates amendments were made, but the specific details of these amendments are not provided in the excerpt.
What matters were submitted to a vote of security holders?
The filing states that matters were submitted to a vote of security holders, but the nature of these matters is not detailed in the provided text.
What financial statements and exhibits are being filed?
The filing confirms the submission of financial statements and exhibits, but the specific content of these documents is not described in the excerpt.
When was Outlook Therapeutics formerly known as Oncobiologics, Inc.?
The date of the name change from Oncobiologics, Inc. to Outlook Therapeutics, Inc. was August 4, 2015.
What is the principal executive address of Outlook Therapeutics?
The principal executive address is 485 Route 1 South, Building F, Suite 320, Iselin, New Jersey 08830.
Filing Stats: 1,109 words · 4 min read · ~4 pages · Grade level 12 · Accepted 2024-03-07 16:16:07
Filing Documents
- tm248235d1_8k.htm (8-K) — 57KB
- tm248235d1_ex3-1.htm (EX-3.1) — 7KB
- 0001104659-24-031908.txt ( ) — 243KB
- otlk-20240307.xsd (EX-101.SCH) — 3KB
- otlk-20240307_lab.xml (EX-101.LAB) — 34KB
- otlk-20240307_pre.xml (EX-101.PRE) — 22KB
- tm248235d1_8k_htm.xml (XML) — 4KB
03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year At the 2024 Annual Meeting of Stockholders (the "Annual Meeting"), the stockholders of Outlook Therapeutics, Inc. (the "Company") approved an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the authorized number of shares of the Company's common stock from 425,000,000 to 1,200,000,000 shares. The increase in the authorized number of shares of the Company's common stock was effected pursuant to a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the "Certificate of Amendment") filed with the Secretary of State of the State of Delaware on March 7, 2024 and was effective as of such date. The foregoing description is qualified in its entirety by the Certificate of Amendment, which is attached as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders At the Annual Meeting held on March 7, 2024, the Company's stockholders voted on eight proposals, each of which is described in more detail in the Company's proxy statement on Schedule 14A filed with the Securities and Exchange Commission on February 8, 2024 (the "Proxy Statement"). Of the 260,257,517 shares of the Company's common stock outstanding as of the record date, 194,030,258 shares, or approximately 74.6%, were present or represented by proxy at the Annual Meeting. The following is a brief description of each matter voted upon and the certified results, including the number of votes cast for and against each matter and, if applicable, the number of votes withheld, abstentions and broker non-votes with respect to each such matter. Proposal 1. Stockholders elected each of the following nominees to serve as Class II directors on the Company's Board of Directors (the "Board") until the Company's 2027 Annual Meeting of Stockholders or until his or her successor has been duly elected and qualified. The voting results for such nominees were as follows: Director Name Votes For Votes Withheld Broker Non- Votes Gerd Auffarth, M.D. 122,406,604 7,573,738 64,049,916 Julia A. Haller, M.D. 126,307,671 4,173,076 63,549,511 Andong Huang 128,730,972 1,749,775 63,549,511 Lawrence A. Kenyon 125,464,513 4,524,055 64,041,690 Proposal 2. Stockholders approved the potential issuance in excess of 19.99% of the Company's outstanding common stock in a private placement of shares of common stock and accompanying warrants at less than the "minimum price" under Nasdaq Listing Rule 5635. The voting results were as follows: Votes For Votes Against Abstentions Broker Non- Votes 123,467,622 6,224,132 788,993 63,549,511 Proposal 3. Stockholders approved the potential issuance in excess of 19.99% of the Company's outstanding common stock upon the conversion of an outstanding convertible note
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 3.1 Certificate of Amendment of the Amended and Restated Certificate of Incorporation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Outlook Therapeutics, Inc. Date: March 7, 2024 By: /s/ Lawrence A. Kenyon Lawrence A. Kenyon Chief Financial Officer